Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.

[1]  Do Young Kim,et al.  Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma , 2020, Clinical and molecular hepatology.

[2]  Jun Kato,et al.  Switching to systemic therapy after locoregional treatment failure: Definition and best timing , 2020, Clinical and molecular hepatology.

[3]  F. Piscaglia,et al.  Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. , 2019, Journal of hepatology.

[4]  M. Kudo,et al.  CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) , 2019, Annals of Oncology.

[5]  Kehua Zhou,et al.  Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma , 2019, Cancers.

[6]  M. Kudo,et al.  Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). , 2019, Journal of Clinical Oncology.

[7]  M. Kudo.  Systemic Therapy for Hepatocellular Carcinoma: Latest Advances , 2018, Cancers.

[8]  I. Grivicich,et al.  Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience , 2018, Digestive Diseases.

[9]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[10]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[11]  M. Kudo,et al.  Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib , 2018, Zeitschrift für Gastroenterologie.

[12]  Joong-Won Park,et al.  Epidemiology of liver cancer in South Korea , 2017, Clinical and molecular hepatology.

[13]  Alan D. Lopez,et al.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.

[14]  F. Camacho,et al.  The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology. , 2015, The oncologist.

[15]  O. Yokosuka,et al.  Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors , 2015, Investigational New Drugs.

[16]  G. Spolverato,et al.  Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. , 2015, Journal of hepatology.

[17]  S. Ye,et al.  Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Bang,et al.  Non–Laboratory-Based Self-Assessment Screening Score for Non-Alcoholic Fatty Liver Disease: Development, Validation and Comparison with Other Scores , 2014, PloS one.

[19]  M. Brose,et al.  Management of sorafenib-related adverse events: a clinician's perspective. , 2014, Seminars in oncology.

[20]  L. Jeng,et al.  Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Y. Paik,et al.  Clinical parameters predictive of outcomes in sorafenib‐treated patients with advanced hepatocellular carcinoma , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[22]  P. Elias,et al.  Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression , 2012, The Journal of investigative dermatology.

[23]  M. Kudo,et al.  Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. , 2011, European journal of cancer.

[24]  Z. Wu,et al.  Meta‐analysis of dermatological toxicities associated with sorafenib , 2011, Clinical and experimental dermatology.

[25]  M. Yoshikawa,et al.  Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma , 2011, Hepatology international.

[26]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[27]  H. Kong,et al.  Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. , 2008, The oncologist.

[28]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[29]  M. Lacouture,et al.  Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis , 2008, Acta oncologica.

[30]  B. Goldspiel,et al.  Sorafenib and Sunitinib: Novel Targeted Therapies for Renal Cell Cancer , 2007, Pharmacotherapy.

[31]  E. Proksch,et al.  Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. , 1996, Acta dermato-venereologica.

[32]  S. Kaasa,et al.  The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. , 1994, European journal of cancer.